Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | TP53 | P04637 | 7/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12008145 | 0.94 | MAPT (0.73) | MAPTLMNATP53POLBSMN1; SMN2 | |
| SCHEMBL13694824 | 0.90 | MAPT (0.60) | MAPTLMNATP53POLBSMN1; SMN2 | |
| SCHEMBL12008148 | 0.88 | MAPT (0.74) | MAPTLMNATP53POLBSMN1; SMN2 | |
| SCHEMBL12008295 | 0.88 | MAPT (0.70) | MAPTLMNATP53SMN1; SMN2TSHR | |
| SCHEMBL12008294 | 0.88 | MAPT (0.67) | MAPTLMNATP53POLBSMN1; SMN2 | |
| SCHEMBL12008150 | 0.87 | SMN1; SMN2 (0.61) | MAPTLMNATP53POLBSMN1; SMN2 | |
| SCHEMBL14901098 | 0.87 | MAPT (0.60) | MAPTLMNATP53POLBSMN1; SMN2 | |
| SCHEMBL13446794 | 0.86 | MAPT (0.73) | MAPTLMNATP53POLBSMN1; SMN2 | |
| SCHEMBL12008302 | 0.85 | MAPT (0.68) | MAPTLMNATP53POLBSMN1; SMN2 | |
| SCHEMBL12008160 | 0.84 | MAPT (0.83) | MAPTLMNATP53POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
| US-9433611-B2 | Oxazole and thiazole compounds as β-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9173871-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
| US-20120264744-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | UNITED STATES GOVERNMENT | 2012-10-18 | — | — | US | disclosed |
| US-8252823-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252823-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | US ARMY, SECRETARY OF THE ARMY | 2009-09-10 | — | — | US | disclosed |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | US ARMY, SECRETARY OF THE ARMY | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264744-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | MAPT 2143/4885LMNA 3384/4885TP53 91/4885 |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | CTNNB1, CTNNA1, CTNNBL1 | MAPT 1929/4885LMNA 4032/4885TP53 73/4885 |
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | MAPT 1929/4885LMNA 4032/4885TP53 73/4885 |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | MAPT 1929/4885LMNA 4032/4885TP53 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.